Vinflunine
- Generic Name
- Vinflunine
- Brand Names
- Javlor
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54F2N4O8
- CAS Number
- 162652-95-1
- Unique Ingredient Identifier
- 5BF646324K
- Background
Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis . Vinflunine is a microtubule inhibit...
- Indication
For use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing therapy .
- Associated Conditions
- Transitional Cell Carcinoma of the Urothelial Tract, Metastatic Transitional Cell Carcinoma of the Urothelial Tract
- Associated Therapies
- -
Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Dr Anders Ullén
- Target Recruit Count
- 22
- Registration Number
- NCT01844947
- Locations
- 🇩🇰
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
🇸🇪Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
🇩🇰Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
- Conditions
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Associació per a la Recerca Oncologica, Spain
- Target Recruit Count
- 372
- Registration Number
- NCT01830231
- Locations
- 🇳🇱
St. Antoniusziekenhuis, Nieuwegein, Netherlands
🇳🇱Vumc Amsterdam, Amsterdam, Netherlands
🇳🇱NKI-AvL, Amsterdam, Netherlands
Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 86
- Registration Number
- NCT01529411
- Locations
- 🇪🇸
Hospital Fundació Althaia, Manresa, Barcelona, Spain
🇪🇸ICO-Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-03-23
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 594
- Registration Number
- NCT01091168
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00545766
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
- Conditions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00534807
- Locations
- 🇺🇸
Local Institution, Detroit, Michigan, United States
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00519831
- Locations
- 🇺🇸
Alamance Oncology/Hematology Associates, LLP, Burlington, North Carolina, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Registration Number
- NCT00450515
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 34
- Registration Number
- NCT00389155
- Locations
- 🇺🇸
Medical College Of Georgia, Augusta, Georgia, United States
🇺🇸Nevada Cancer Centers, Las Vegas, Nevada, United States
🇺🇸Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States
A Study of Vinflunine in Patients With Gastric Cancer
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 55
- Registration Number
- NCT00359476
- Locations
- 🇵🇭
Local Institution, Quezon City, Philippines
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.